ImmuPharma plc (LON:IMM – Get Free Report)’s share price was down 27.1% on Monday . The stock traded as low as GBX 6.52 and last traded at GBX 7.12. Approximately 25,940,547 shares traded hands during mid-day trading, an increase of 225% from the average daily volume of 7,976,025 shares. The stock had previously closed at GBX 9.76.
ImmuPharma Price Performance
The firm has a market cap of £33.68 million, a PE ratio of -7.53 and a beta of 1.53. The business has a 50-day moving average price of GBX 11.18 and a two-hundred day moving average price of GBX 5.81.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- What Are Dividend Champions? How to Invest in the Champions
- Hims, Block, and NRG Just Launched Huge Stock Buybacks
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- JPMorgan and Goldman Upgrade MP Materials Amid Defense-Driven Demand Outlook
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
